Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 1, 1997, Pages 54-60

  Gilliam, Bruce L ^a,b   Dyer, John R ^a   Fiscus, Susan A ^a   Marcus, Cheryl ^a   Zhou, Susan ^b   Wathen, Lynne ^c   Freimuth, William W ^c   Cohen, Myron S ^a   Eron Jr , Joseph J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

Antiretroviral therapy; HIV 1 quantitative microculture; HIV 1 RNA; Human immunodeficiency virus; Nucleic acid sequence based amplification (NASBA) assay; Semen

Indexed keywords

DELAVIRDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RNA ANALYSIS; SPERM; VIRUS DETECTION; VIRUS SHEDDING; VIRUS TITRATION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030858596     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199705010-00009     Document Type: Article

References (29)

1. Mayer KH, Anderson DJ. Heterosexual HIV transmission. Infect Agents Dis 1995;4:273-84.
2. Eron J, Gilliam B, Fiscus S, Dyer J, Cohen M. HIV-1 shedding and chlamydial urethritis. JAMA 1996;275:36.
3. Vernazza PL, Eron JJ, Cohen MS, van der Horst CM, Troiani L, Fiscus SA. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS 1994;8: 1325-9.
4. Dyer J, Gilliam B, Eron J, Grosso L, Cohen M, Fiscus S. Quantitation of HIV-1 RNA in cell-free seminal plasma by NASBA amplification and Amplicor reverse transcription PCR: a comparative study. J Virol Methods 1996;60:161-70.
5. Hoffman I, Maida M, Royce R, et al. Effect of urethritis therapy on the concentration of HIV-1 in seminal plasma [abstract Mo.C.903]. Presented at the XI International Conference on AIDS, Vancouver, BC, July 7-12, 1996.
6. Atkins MC, Carlin EM, Emery VC, Griffiths PD, Boag F. Fluctuations of HIV load in semen of HIV-positive patients with newly acquired sexually transmitted disease. BMJ 1996; 313:341-2.
7. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
8. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333: 1662-9.
9. Anderson DJ, O'Brien TR, Politch JA, et al. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA 1992;267:2769-74.
10. Krieger JN, Coombs RW, Collier AC, et al. Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol 1995;154:1035-40.
11. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus type 1 in semen: effect of disease stage and nucleoside therapy. J Infect Dis 1993;167:798-802.
12. Dueweke TJ, Poppe SM, Romero DL, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication Antimicrob Agents Chemother 1993;37:1127-31.
13. Freimuth W, Wathen L, Cox SR, et al. Delavirdine in combination with zidovudine causes sustained antiviral and immunological effect in HIV-1 infected individuals [abstract LB8a]. Presented at the Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 28-February 1, 1996.
14. Freimuth W, Chuang-Stein C, Greenwald C, et al. Delavirdine and didanosine combination therapy has sustained surrogate marker response in advanced HIV-1 population [abstract LB8b]. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
15. Fiscus SA, DeGruttola V, Gupta P, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995;171:305-11.
16. Van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994;49:157-67.
17. Wathen L, Nickens D, Chuang-Stein C, et al. Viral burden at baseline or its reduction following antiretroviral therapy is highly correlated with reduced HIV-1 disease progression [abstract LB8c]. Presented at th Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
18. Searle SR, Casella G, McCulloch CE. Variance components. New York: John Wiley & Sons, 1992.
19. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994;32:732-9.
20. Phillips A, Eron J, Bartlett J, et al. Serial HIV RNA levels and the development of clinical disease in HIV-1 infection. AIDS 1996;10:859-65.
21. Fiscus SA, Royce R, Eron JJ. Quality control of HIV cultures in a clinical retrovirology laboratory. J Virol Methods 1996; 58:91-8.
22. Henry K, Chinnock JB, Quinn RP, Fletcher CV, de Miranda P, Balfour H Jr. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988;259:3023-6.
23. Fletcher CV, Chinnock B, Henry K, Balfour HH Jr. A pharmacokinetic model for zidovudine in semen [abstract 3657]. Presented at the Fourth International Conference on AIDS, Stockholm, June 12-16, 1988.
24. Busch M, Operskalski E, Mosley J, et al. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. J Infect Dis 1996;174:26-33.
25. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment of viral load [see comments]. JAMA 1996;275:599-605.
26. Fang G, Burger H, Grimson R, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995;92:12100-4.
27. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission: Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994;154:1971-6.
28. Perelson A, Neumann A, Markowitz M, Leonard J, Ho D. HIV-1 dynamic in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 1996;271:1582-6.
29. Merson MH. Slowing the spread of HIV: agenda for the 1990s. Science 1993;260:1266-8.